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Rare Bone Diseases and Their Dental, Oral, and Craniofacial Manifestations
Abstract
Hereditary diseases affecting the skeleton are heterogeneous in etiology and severity. Though many of
these conditions are individually rare, the total number of people affected is great. These disorders often
include dental-oral-craniofacial (DOC) manifestations, but the combination of the rarity and lack of indepth reporting often limit our understanding and ability to diagnose and treat affected individuals. In this
review, we focus on dental, oral, and craniofacial manifestations of rare bone diseases. Discussed are
defects in 4 key physiologic processes in bone/tooth formation that serve as models for the
understanding of other diseases in the skeleton and DOC complex: progenitor cell differentiation (fibrous
dysplasia), extracellular matrix production (osteogenesis imperfecta), mineralization (familial tumoral
calcinosis/hyperostosis hyperphosphatemia syndrome, hypophosphatemic rickets, and
hypophosphatasia), and bone resorption (Gorham-Stout disease). For each condition, we highlight
causative mutations (when known), etiopathology in the skeleton and DOC complex, and treatments. By
understanding how these 4 foci are subverted to cause disease, we aim to improve the identification of
genetic, molecular, and/or biologic causes, diagnoses, and treatment of these and other rare bone
conditions that may share underlying mechanisms of disease.
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Rare Bone Diseases and Their Dental,
Oral, and Craniofacial Manifestations
B.L. Foster1*, M.S. Ramnitz2, R.I. Gafni3, A.B. Burke3, A.M. Boyce3,4,5, J.S. Lee6, J.T. Wright7, S.O. Akintoye8,
M.J. Somerman1,9, and M.T. Collins3

Abstract: Hereditary diseases affecting
the skeleton are heterogeneous in etiology and severity. Though many of these
conditions are individually rare, the
total number of people affected is great.
These disorders often include dentaloral-craniofacial (DOC) manifestations, but the combination of the rarity and lack of in-depth reporting often
limit our understanding and ability
to diagnose and treat affected individuals. In this review, we focus on dental, oral, and craniofacial manifestations of rare bone diseases. Discussed
are defects in 4 key physiologic processes in bone/tooth formation that
serve as models for the understanding of other diseases in the skeleton
and DOC complex: progenitor cell differentiation (fibrous dysplasia), extracellular matrix production (osteogenesis imperfecta), mineralization
(familial tumoral calcinosis/hyperostosis hyperphosphatemia syndrome,
hypophosphatemic rickets, and hypophosphatasia), and bone resorption
(Gorham-Stout disease). For each condition, we highlight causative mutations (when known), etiopathology in

the skeleton and DOC complex, and
treatments. By understanding how
these 4 foci are subverted to cause disease, we aim to improve the identification of genetic, molecular, and/or biologic causes, diagnoses, and treatment
of these and other rare bone conditions
that may share underlying mechanisms
of disease.
Key Words: fibrous dysplasia
of bone, osteogenesis imperfecta,
familial hypophosphatemic rickets,
hypophosphatasia, hyperphosphatemic
familial tumoral calcinosis, Gorham-Stout
disease.
Introduction
Hereditary diseases affecting the
skeleton, which we define to include
the craniofacial and dental structure,
are heterogeneous in etiology, onset,
and severity. Although many of these
conditions are individually rare (affecting
less than 1 in 200,000), the total number
of people affected is great (see the
National Organization for Rare Disorders
at www.rarediseases.org and the Rare

Bone Disease Patient Network at
http://www.usbji.org/projects/RBDPN_
op.cfm). Rare disorders are difficult to
diagnose and are easily misdiagnosed;
those of the skeleton are no exception.
While progress has been made in
our understanding of the underlying
causes, pathologies, and mechanisms
of bone diseases, those of the dentaloral-craniofacial (DOC) complex are
frequently overlooked or superficially
reported. This has implications in terms
of understanding, diagnosing, and
treating affected individuals, in turn
affecting health and quality of life.
Proper formation of the skeleton
and dentition requires integration of
numerous processes beginning in early
embryonic development. These include
patterning of the head, limbs, and
skeletal/dental elements, cell migration
and proliferation, differentiation to
specialized cells, matrix secretion,
biomineralization of bones and teeth,
and remodeling of bone. For purposes
of this review, we discuss 4 processes
directly affecting the formation and
function of craniofacial bones and teeth
(Fig. 1) that can serve as models for an
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Figure 1.
Diseases affecting specific stages of bone formation and remodeling. This model outlines key stages of bone development (differentiation of
stem/progenitor cells, matrix production, mineralization, and resorption) affected by the genetic disorders highlighted in this review. For each
developmental process (indicated by text boxes), associated diseases caused by defects in that process are identified. Tooth development
depends on parallel processes outlined for bone formation, though notably does not undergo physiological resorption as part of a remodeling
process.

understanding of basic pathophysiologic
processes in the broader sense:
progenitor cell differentiation,
extracellular matrix production,
mineralization, and resorption, a key step
in remodeling of bone, but not teeth. For
each of these processes, we highlight a
disease or small number of diseases that
occur(s) when that stage goes awry. By
discussing mechanisms of how bone and
tooth functions are negatively affected in
these specific cases, we aim to identify
patterns that can ultimately be applied
to improve the identification of genetic,
molecular, and/or biologic causes of
additional diseases by their shared
skeletal and dental etiopathologies.
Appendix Table 1 summarizes additional
conditions under each disease process.
8S

Defective Stem/Progenitor
Cell Differentiation
Fibrous Dysplasia

Fibrous dysplasia of bone (FD; MIM
174800) is caused by somatic activating
mutations in the GNAS gene encoding the
G-protein-coupled receptor-associated
3′, 5′-cyclic adenosine monophosphate
(cAMP)-regulating protein, Gsα.
Mutations result in ligand-independent
activation of the cAMP signaling pathway
(Weinstein et al., 1991). In skeletal tissues,
overproduction of cAMP impairs the
ability of bone-forming mesenchyme
to transition from stem-like immature
cells to mature osteogenic cells. There
is increased secretion of interleukin-6
and expression of receptor activator for

NFκB ligand (RANKL), both of which
contain cAMP response elements in their
promoters (Riminucci et al., 2003). The
outcome is abnormal bone formation
and remodeling characterized by fibrous
tissue proliferation and expansion of the
marrow or diploë by fibrous tissue that
contains immature, structurally abnormal
woven bone (Riminucci et al., 1997).
The phenotype is broad, ranging from
a single skeletal site (monostotic) to
massive disease affecting multiple bones
(polyostotic) (Fig. 2A). The phenotype is
determined by when, and in which clonal
cell in the inner cell mass, the sporadic
mutation arises during development. The
degree of clinical sequelae likewise varies,
from asymptomatic to disfigurement
with loss of function, including blindness
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and deafness. When extra-skeletal sites
are involved, such as skin (café-aulait macules) (Fig. 2B) and/or gonads
(precocious puberty) (Fig. 2C), the
disease is known as McCune-Albright
syndrome (MAS). Hyperthyroidism,
hypophosphatemia, and growth hormone
excess can also occur in FD/MAS
(Figs. 2D, 2E). Craniofacial bones are
the most commonly involved skeletal
sites in FD, especially the skull base,
maxilla, and midface (Lee et al., 2002;
Kelly et al., 2008) (Figs. 2A, 2F, 2G).
There can be extensive expansion of
the skull, maxilla, and mandible, tooth
displacement, severe malocclusion, and
facial disfigurement (Akintoye et al., 2003,
2013) (Figs. 2G-2I). When associated
with pituitary hypersecretion of growth
hormone, overgrowth of craniofacial
FD is associated with greater morbidity.
Panoramic radiographs of jaw FD display
ground glass trabeculation that may
progress to mixed radiolucent/radiopaque
lesions (Figs. 2J, 2K). Dental disorders
associated with FD include enamel
hypoplasia and hypomineralization,
dentin dysplasia, odontoma, taurodontic
pulp, and high caries index (Figs. 2I, 2L,
2M). It is unclear whether FD-related
cAMP excess affects tooth development,
but taurodontism (Fig. 2K) seen in FD
may be the combined effect of FD and
endocrine dysfunction.
Diagnosis of FD and/or MAS involves
careful clinical, radiographic, and
occasionally histopathologic evaluation.
Technetium-99 scintigraphy is useful for
determining sites of skeletal involvement
and disease burden. When this is
combined with computed tomography
(CT), the overall extent of the craniofacial
disease can usually be determined in
individuals by age 5 yr (Hart et al., 2007).
Evaluation should include screening for
hyperthyroidism, hypophosphatemia, and
growth hormone excess. Histopathology
of FD shows immature, irregular, woven
bone, often with ectopic Sharpey’s fibers,
abundant osteoid, in a fibrous stroma of
variable cellularity, and often with active,
osteoclast-mediated bone resorption
(Fig. 2N).
The mainstay of FD treatment
is surgery (Stanton et al., 2012).

Intramedullary fixation devices are
preferred for orthopedic procedures.
However, craniofacial surgery should
be undertaken with caution because of
potential for the rapid regrowth of FD
lesions. Optic nerve decompression is
contraindicated in cases where nerves are
constricted but vision is unaffected (Lee
et al., 2002). Bisphosphonates are helpful
to treat bone pain; however, no clear
radiographic, functional, or histologic
benefits have been demonstrated. There
is evidence suggesting that, with age,
mutant progenitor cells fail to self-renew,
while surviving normal cells are able to
form normal bone, thereby limiting the
progression of FD lesions (Kuznetsov
et al., 2008).
Defective Matrix Function
Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a group
of hereditary disorders characterized by
variable bone fragility. Clinical diversity
led to classification of OI into 4 subtypes
based on clinical phenotype and mode of
inheritance (Sillence et al., 1979). There
are currently 15 OI subtypes caused by
mutations involving 11 genes (Appendix
Table 2). More than 90% of individuals
with OI have heterozygous mutations
in 1 of the 2 genes encoding type I
collagen (CO1A1 and COL1A2), the most
abundant matrix protein in bone, dentin,
ligaments, sclera, and skin. OI types
V-XV are caused by mutations in 1 of at
least 9 different genes (Byers and Pyott,
2012). These OI types are rare (about
10% of total OI cases) compared with
those caused by mutations in CO1A1 and
COL1A2. There are hundreds of allelic
mutations in these genes, and genotypephenotype relationships remain unclear
in many instances, although mutations
affecting different collagen-coding genes
and types of mutations (e.g., splice
mutations vs. glycine substitutions) are
associated with differing degrees of
clinical severity (Marini et al., 2007).
Other causative genes for OI affect
crosslinking and stabilization of the
collagen fibril (e.g. PLOD2, FKBP10)
or mineralization of fibrils (e.g., BMP1,
which cleaves the C-terminus of

collagen propeptide) (Byers and
Pyott, 2012; Martinez-Glez et al.,
2012).
Craniofacial and dental features for
OI types III and IV are summarized
in Fig. 3. Affected individuals suffer
from decreased bone mineral density,
increased fracture risk, deformations,
short stature, kyphoscoliosis, craniofacial
deformities, and a tooth phenotype
resembling dentinogenesis imperfecta
(DI). Wormian bones (intrasutural
bones with unusually situated centers
of ossification) are associated with OI
and have been correlated with disease
severity (Semler et al., 2010). Additional
clinical manifestations include blue
sclera, easy bruising, hearing loss, joint
hypermobility, and hernias (van Dijk
et al., 2011). DI-affected teeth tend to
be smaller than normal, and feature
constriction at the cementum-enamel
junction, diminished roots, blue-gray
to yellow-brown discoloration, and
pulp chambers that are progressively
diminished and appear obliterated on
radiographs (Majorana et al., 2010). It
is unclear why some OI mutations are
associated with a DI phenotype, while
others are not.
Clinical manifestations of OI are
managed by a combination of intraosseous rods to reduce long bone
fractures (Mulpuri and Joseph, 2000) and
bisphosphonate infusions to improve
bone density and manage bone pain
(Ruck et al., 2011; Nicolaou et al., 2012).
Oral bisphosphonates have been used
with some success in milder OI cases.
Despite concerns about bisphosphonateinduced osteonecrosis of the jaw,
to date there are no reports of this
condition in patients with OI treated with
bisphosphonates (Milano et al., 2011;
Christou et al., 2013).
Management of the dentition when
DI is present depends on the severity,
and whether enamel fracturing
occurs and results in excessive tooth
breakdown. Crowning of the teeth is
the treatment of choice in these cases,
since intra-coronal restorations are not
retained in DI teeth that are affected
by enamel loss and excessive dentin
loss.
9S
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Figure 2.
Fibrous dysplasia (FD). (A) Technetium-99 bone scintigraphy of a female patient with FD/McCune-Albright syndrome (MAS) shows patchy
areas of increased radiotracer uptake by FD in the craniofacial bones (black arrowheads), pelvis, and long bones (black arrows). (B) Caféau-lait macules on the face of a boy with MAS macules display the typical jagged “coast of Maine” borders. (C) Testicular ultrasound of
a patient with MAS displays heterogeneous mixed cystic and solid lesions characteristic of Leydig cell hyperplasia (white arrows). (D)
Thyroid ultrasound of a patient with MAS and hyperthyroidism demonstrates characteristic heterogeneity with a cystic, “Swiss cheese”-like
appearance (white arrow). (E) Magnetic resonance imaging of the brain of a patient with MAS-associated growth hormone excess displays a
large, dumbbell-shaped growth-hormone- and prolactin-secreting pituitary macroadenoma (white arrows); the bright spot (black arrowhead)
indicates the posterior pituitary. (F) Computed tomography (CT) of the head in this MAS patient shows right mandibular expansion by FD
(white arrow). (G) Three-dimensional volume rendering of CT images of the same patient seen in panel F shows expansion of FD in the
right mandible (white arrow), as well as smaller potential areas of FD in the right fronto-orbital region and midface (black arrowheads). (H)
Severe expansion of the maxilla by FD (black stars) is associated with malocclusion and right-sided overbite (white arrow). (I) In another FD
patient, malocclusion shows a right lingual crossbite (black arrows) and a left posterior open bite (white arrow), possibly from mandibular
enlargement due to growth hormone excess. (J) Panoramic radiograph of mandibular FD shows radiolucent ground glass trabeculation
(white arrow). (K) Another MAS patient with growth hormone excess displays generalized FD radiopacity, particularly in the maxilla, and
taurodontic pulp chambers (black arrows). (L) Enamel hypomineralization (black arrowheads) and (M) dentin dysplasia (black arrowheads)
are also dental features often seen in patients with FD/MAS. (N) Histologic features of FD shown in Goldner’s trichrome-stained section
include immature irregular woven bone (WB) with Sharpey’s fibers (white arrows) in a fibrous tissue (FT) matrix of variable cellularity. Note
the unmineralized osteoid (white star) indicating osteomalacia, and an osteoclast resorbing bone in Howship’s lacuna (black arrow). Images
in C, D, F, E, and J reproduced with permission from Akintoye et al., 2013. Image in K reproduced with permission from Akintoye et al., 2003.
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Figure 3.
Osteogenesis imperfecta (OI). Clinical and radiographic findings in individuals with OI types III (A-C) and IV (D-F). (A) Facial appearance of
child with OI type III shows a triangular face with prominent forehead and blue sclera. (B) Dentition of this child shows blue-gray discoloration
characteristic of dentinogenesis imperfecta (DI). Discoloration is less pronounced in the maxillary permanent incisors than in the primary
teeth. (C) A panoramic radiograph of the dentition of this child with OI type III shows cervical constriction and large pulp chambers in the
six-year molars (white arrows), and diminished pulp space in the primary dentition (black stars) that has been restored with stainless steel
crowns. (D) A cephalometric radiograph of an adult individual with OI type IV shows midface deficiency and a steep mandibular plane angle.
(E) A panoramic radiograph of the dentition of the same individual displays obliteration of the pulp space and poor contrast of the roots to
the bone due to the hypomineralized dentin (for example, mandibular teeth indicated by black arrows). This individual has required multiple
root canals as a result of pulpal necrosis associated with DI. (F) A panoramic radiograph of an individual with OI type IV showing delayed
dentin formation and large pulp chambers in the early-developing permanent dentition (see white arrows for examples), while the primary
dentition is undergoing pulpal obliteration due to increased dentin formation (see white stars for examples).
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Mineralization Disorders
Familial Tumoral Calcinosis/
Hyperostosis-Hyperphosphatemia
Syndrome

Familial tumoral calcinosis/
hyperostosis-hyperphosphatemia
syndrome (FTC/HHS; MIM 211900) is
an autosomal-recessive disorder arising
from functional deficiency of intact
fibroblast growth factor 23 (iFGF23),
a phosphaturic hormone produced
primarily by osteocytes and osteoblasts.
Prior to secretion into the circulation,
iFGF23 undergoes O-linked glycosylation
by the galactosyl transferase,
ppGalNacT3, encoded by UDP-N-acetylalpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 3
(GALNT3). O-linked glycosylation
protects iFGF23 from cleavage into
inactive fragments by furin-like proprotein convertases (Kato et al., 2006).
iFGF23 signaling requires Klotho, a
co-receptor that converts a generic
fibroblast growth factor (FGF) receptor
into a specific FGF23 receptor (Urakawa
et al., 2006). The underlying genetic
causes of decreased iFGF23 action
include loss-of-function mutations in
FGF23 (Benet-Pages et al., 2005), GALNT3
(Topaz et al., 2004), or KL (Ichikawa et
al., 2007), which encodes Klotho (Farrow
et al., 2011).
Decreased iFGF23 leads to stimulation
of sodium phosphate co-transporters
(NaPi-2a and-2c) and 25-OH-vitamin
D3-1-α–hydroxylase in the proximal renal
tubule. Hyperphosphatemia ensues from
increased renal tubular reabsorption and
increased gastrointestinal absorption
of phosphate (Pi). In addition,
inappropriately normal or frankly elevated
1,25-dihydroxyvitamin D3 [1,25(OH)2D]
may enhance gastrointestinal absorption
of Pi and calcium (Ca2+) (Farrow et al.,
2011). The increased Ca2+ x Pi product
contributes to ectopic calcification
(Yamaguchi et al., 1995).
Clinical manifestations include
periarticular, subcutaneous, and softtissue calcifications that tend to occur
in areas of repeat trauma (Figs. 4A-4D).
Calcifications may be associated with
inflammation – ulceration of the
12S

overlying skin with milky drainage
in severe cases. In addition to visible
and palpable ectopic calcifications,
radiographs often reveal cortical
hyperostosis (Fig. 4E), which may
cause diaphyseal pain of the long bones.
Age-inappropriate calcification of the
thyroid cartilage (Fig. 4F) has been
described in one patient (Dumitrescu
et al., 2009).
Dental findings include short bulbous
teeth, shortened roots, root dilacerations,
thistle-shaped dental pulps, pulp
chamber and root canal obliteration,
and pulp stones (Figs. 4G, 4H) (Burkes
et al., 1991; Dumitrescu et al., 2009).
Radiographs of younger individuals
suggest that abnormal calcification of
the pulp occurs prior to root formation.
Histologically, the root phenotype
resembles dentin dysplasia II (MIM
125420), but the timing of calcification
differs (Burkes et al., 1991). Alterations in
gingiva and “velvety-red” lesions on the
palate, mucosa, and tongue were noted
in one family (Gal et al., 1994). However,
other reports found no soft-tissue
changes in the oral mucosa of patients
with FTC/HHS. Large bilateral mandibular
tori and bony sclerosis of the mandible,
maxilla, and skull were reported in one
patient (Krstevska et al., 2012).
Treatments for FTC/HHS have not been
well-studied, and there is no standard
regimen. Most reported therapies focus
on lowering serum Pi. A low-Pi diet is
generally encouraged, although difficult
for many to achieve. Pi binders such
as sevelamer and aluminum hydroxide
may decrease Pi absorption in the
gastrointestinal tract. Medications that
promote renal excretion of Pi, such
as acetazolamide and probenecid,
are also used (Yamaguchi et al.,
1995; Lammoglia and Mericq, 2009).
Clinical responses vary, ranging from
complete resolution of calcific tumors
to development of additional ectopic
calcifications. When inflammation is
present, anti-inflammatory medications
may be beneficial. Surgical debulking
is sometimes necessary in patients with
functional impairment or severe pain, but
is not routinely done, since tumors often
recur.

Hypophosphatemic Rickets

Rickets arises from defects in factors
that regulate mineral ion homeostasis,
including 1,25(OH)2D and FGF23,
described above. 1,25(OH)2D functions
in biomineralization by stimulating
gastrointestinal absorption of Ca2+ and
Pi, and initiating cell signaling via the
intracellular vitamin D receptor (VDR).
While the causes of rickets can be
classified as primarily calciopenic or
phosphopenic, evidence suggests that
growth plate defects are primarily due to
hypophosphatemia. In calciopenic forms
of rickets, both nutritional vitamin D
deficiency and rare inherited conditions
affecting vitamin D action [loss-offunction of 1α(OH)ase from CYP27B1
mutations in vitamin D-dependent rickets
type 1, VDDR-I (MIM 264700), or loss
of VDR function in VDDR-IIa (MIM
277440)], lead to hypocalcemia and
hypophosphatemia (the latter induced by
secondary hyperparathyroidism).
Many hereditary forms of primary
hypophosphatemic rickets arise
from mutations affecting renal Pi
handling. The most common type of
hypophosphatemic rickets is X-linked
hypophosphatemia (XLH; MIM 307800),
caused by inactivating mutations in PHEX
(phosphate-regulating endopeptidase
homolog, X-linked). More recently,
mutations in the gene for dentin matrix
protein 1 (DMP1) were linked with type
1 autosomal-recessive hypophosphatemic
rickets (ARHR1; MIM 241520). This was
a surprise, since DMP1 was known as
an extracellular matrix protein in dentin
and bone. ARHR also results from
mutations in the ENPP1 gene encoding
ectonucleotide pyrophosphatase
phosphodiesterase 1 (ARHR2; MIM
613312), a membrane-bound ectoenzyme.
Loss-of-function of ENPP1 was previously
associated with generalized arterial
calcification of infancy. It remains
unclear why the disparate mutations
responsible for XLH, ARHR1, and
ARHR2 all result in elevated iFGF23.
Increased iFGF23 is thought to be the
driving force for hypophosphatemia and
reduced 1,25(OH)2D, which contribute
to disturbances in skeletal and dental
mineralization. Autosomal-dominant
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Figure 4.
Familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome (FTC/HHS). Clinical, radiographic, and histologic findings of patients
with FTC/HHS. (A) Erythematous, inflamed subcutaneous calcifications of the neck and (B) periarticular ectopic calcification of the elbow
in a 9-year-old girl. (C) Radiograph with extensive periarticular ectopic calcification of the right hip (white arrows). (D) Histology of ectopic
calcification with amorphous calcium deposits (arrowheads) surrounded by a thick infiltration of mono- and poly-nucleated macrophages
(“foreign body macrophages”), associated with a chronic inflammatory reaction. (E) Radiograph showing periarticular ectopic calcification
of the right elbow (white arrow) and diaphyseal hyperostosis of the radius and humerus (white arrowheads). (F) Lateral neck radiograph
showing age-inappropriate calcification of the thyroid cartilage in a 36-year-old woman (white arrow). (G) Panoramic dental radiograph
of a 9-year-old girl with blunted, bulbous roots and obliteration of the pulp chamber in the maxillary and mandibular permanent central
and lateral incisors. The erupting permanent premolars exhibit calcification at the root apices. Sclerotic bony changes are also present
around the erupting teeth (white arrows). (H) Periapical radiograph of mandibular right sextant showing thistle-shaped roots (white arrows),
midroot bulges (white arrowheads), and mineralized molar pulps and root canals (white star) in a 36-year-old woman. Images in F and H
reproduced with permission from Dumitrescu et al., 2009.
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hypophosphatemic rickets (ADHR; MIM
193100), with a similar clinical and
biochemical phenotype, is caused by
missense mutations in the FGF23 gene,
resulting in a proteolytically resistant
FGF23, thus increasing circulating iFGF23.
The skeletal manifestations of these
disorders can be separated into
rickets, growth plate abnormalities that
occur in children, and osteomalacia,
defective mineralization that occurs
throughout the skeleton in children and
adults. Rickets manifests clinically as
widening of the distal long bones, often
evident at the wrists, knees, ankles,
and ribs, radiographically as widened
growth plates with frayed and cupped
metaphyses (Fig. 5A). Osteomalacia,
causing bowing deformities, is a tissue
diagnosis where staining demonstrates
unmineralized (osteoid) matrix (as in
Fig. 2N or 5I). Craniofacial manifestations
include enlarged cranial sutures, delayed
fontanelle closure, craniotabes (skull
bone thinning and softening), and
malformations of the cranium, including
parietal and occipital flattening and
frontal bossing. Craniosynostosis has
been documented in VDDR and XLH,
often in the second or third year of life,
leading to scaphocephaly (anteriorposterior elongation of the cranium),
elevated intracranial pressure, and
papilledema (optic disc swelling)
(Glass et al., 2011) (Figs. 5B, 5C).
Cephalometric analysis in patients
with osteomalacia shows alterations
in bones of both endochondral and
intramembranous origin (Gjørup et al.,
2011). While the mineralization disorders
and malformations are explained by
hyperosteoidosis, the etiology for
craniosynostosis remains unclear. One
hypothesis involves FGF23-FGFR2
signaling in the areas of the sutures.
Delayed tooth eruption is frequently
cited in cases of XLH (Foster et al.,
2014). There have been several case
reports on dental manifestations of
VDDR and XLH, and limited numbers
of publications on ARHR and ADHR
are consistent with these pathologies.
The rachitic tooth features defects in all
the dental hard tissues. These include
hypoplastic enamel that is easily abraded
14S

and fractured and subject to caries, thin
and poorly mineralized dentin, enlarged
pulp chambers, predisposition to dental
abscesses, short and malformed roots,
periodontal disease, and sometimes
malocclusion (Figs. 5D-5G). Animal
studies show that enamel defects arise
from a combination of altered vitamin D
metabolism along with hypocalcemia
and hypophosphatemia (Berdal
et al., 2011). Dentin mineralization is
consistently affected across all forms
of hypophosphatemic rickets, with the
histologic presence of interglobular
dentin indicating inhibition of growth of
mineralization foci, likely arising from
a combination of hypophosphatemia,
elevated levels of circulating mineral
inhibitors, and reduced active
1,25(OH)2D. The hypomineralized dentin
is prone to fractures and predisposes
teeth to infection and abscess.
Periodontal problems likely arise from
a combination of osteomalacia in the
alveolar bone and root surface defects in
the cementum (Foster et al., 2014).
Vitamin D disorders are treated
with vitamin D analogues and Ca2+;
VDDR-II is refractory to calcitriol due
to impaired VDR function. Children
with hypophosphatemic rickets are
typically administered calcitriol and Pi,
which can improve skeletal (and dental)
manifestations (Chaussain-Miller et al.,
2007). In cases of craniosynostosis,
surgical interventions such as cranial
vault expansion are necessary to allow
for cranial growth and to alleviate
intracranial pressure (Murthy, 2009).
Hypophosphatasia

Hypophosphatasia (HPP) is
characterized by poor bone
mineralization resulting from loss-offunction mutations in ALPL, encoding
tissue-nonspecific alkaline phosphatase
(TNAP) (Whyte, 1994). More than 267
HPP-associated mutations in ALPL have
been identified, passed in dominant
or recessive mode (http://www.sesep.
uvsq.fr/03_hypo_mutations.php). TNAP
is an ectoenzyme that hydrolyzes (thus
reducing) inorganic pyrophosphate (PPi),
a potent mineralization inhibitor. In
addition to expression by chondrocytes

and osteoblasts, TNAP is found in the
dentoalveolar complex, with wide
expression in the periodontium, dentinpulp complex, and enamel organ (Foster
et al., 2012).
Six clinical forms of HPP have been
identified, varying in severity and age of
onset (Reibel et al., 2009). Infantile and
childhood HPP (MIM 241500, 241510)
causes a widely hypomineralized
skeleton (including rickets), short stature,
and waddling gate. Adult HPP (MIM
146300) presents during middle age and
features osteomalacia, bone pain, and
stress fractures (Figs. 5H, 5I) (Berkseth
et al., 2013). An intriguing aspect of
HPP is the tooth-specific clinical isotype,
odontohypophosphatasia, in which
serum ALP is decreased and urinary
phosphoethanolamine increased, but
skeletal development is not (evidently)
impaired, and tooth loss is the primary
clinical sign (Mornet, 2007).
Severe forms of HPP feature
hypomineralized regions of calvarial
bone that radiographically appear
as widely open fontanelles, though
functional craniosynostosis (closure) can
occur, leading to increased intracranial
pressure and a bulging anterior fontanel
(Whyte, 1994; Collmann et al., 2009)
(Figs. 5J, 5K). Wormian bones are
sometimes present in infantile and
childhood HPP.
Observations of premature tooth loss
led to the finding that root acellular
cementum is defective in HPP, resulting
in compromised periodontal attachment
(Figs. 5L-5O). Reduction in alveolar
bone height reflects bone loss due to
poor periodontal attachment. Defects
in dentin and enamel mineralization
have been reported, though not
consistently. The dentin phenotype
includes widened pulp chambers, “shell
teeth” with thin root dentin, and short,
abnormally shaped roots (Figs. 5L-5N),
related to developmental defects in the
initial mantle dentin layer (Foster et al.,
2012), likely parallel to effects causing
osteomalacic bone and similar to effects
in hypophosphatemic rickets, described
above.
Results from translational studies
and clinical trials with a recombinant
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Figure 5.
X-linked hypophosphatemic rickets (XLH) and hypophosphatasia (HPP). Representative images of individuals with hypophosphatemic rickets (AG) and hypophosphatasia (H-O). (A) Skeletal pathology resulting from osteomalacia includes bowing of the femur (arrow) due to softening of the
bone. (B) The computed tomography (CT) scan of a 3-year-old female with XLH shows scaphocephaly (elongation of the skull), suggestive of
premature fusion of the sagittal suture. (C) Brain CT (left image) from the same patient shows enlargement of optic nerve sheaths (red arrows) due
to papilledema (optic disc swelling), while orbital CT shows ventricular narrowing and decreased size of ventricles (white arrows) due to synostoses,
contributing to elevated intracranial pressure. (D) Enamel discoloration indicating hypoplasia in a juvenile individual diagnosed with XLH, and (E)
dental radiograph from the same individual features thin dentin and wide pulp chambers (white arrows). (F) Histologic staining reveals interglobular
dentin hypomineralization, reflecting inhibition of mineralization foci to fuse into a unified mineralization front, a pattern replicated in (G) scanning
electron microscopy from an adult individual with XLH. (H) Radiograph of pseudofracture of the proximal femur (white arrow) in adult diagnosed
with HPP. (I) Goldner’s trichrome stain of iliac crest biopsy from adult diagnosed with HPP, exhibiting excess osteoid (red layer indicated by black
arrow). (J) Magnetic resonance imaging (MRI) of the skull of a six-year-old individual diagnosed with childhood HPP exhibiting craniosynostosis
and resulting bregmatic eminence (white arrow). (K) Radiograph of a four-year-old HPP individual with hypomineralization of cranial vault exhibiting
severe “copper beaten” skull appearance, as well as deformations of cranial vault shape. Alterations in cranial shape in J and K are indicative of
increased cranial pressure. (L) Clinical photograph of a fourteen-year-old individual with HPP who experienced spontaneous exfoliation of the lower
mandibular incisor during toothbrushing. (M) Panoramic radiograph of the same individual revealing delayed eruption of several permanent teeth
(e.g., lower premolars), enlarged pulp chambers, and thin dentin. (N) Periapical radiograph of the same patient at 20 yr old, showing loss of lower
incisor, endodontic treatment, and splinting of remaining incisors, with generalized loss of alveolar bone. (O) Scanning electron microscopy of incisor
root from HPP patient indicates lack of cementum and exposure of dentin (*), as well as extensive resorption over the root surface. Images in B and
C adapted from Glass et al. (2011); reproduced under open access policy. Images in D-F are adapted from Pereira et al. (2004) and are reproduced
with permission. Image in G was adapted from Foster et al. (2013) and is reproduced by permission. Images in H and I are adapted from Berkseth
et al. (2013) and are reproduced with permission. Images in J and K are adapted from Collmann et al. (2009) and are reproduced with permission.
Images in L, M, and O are adapted from Rodrigues et al. (2012) and are reproduced with permission. Image in N is adapted from Rodrigues et al.
(2012), and is reproduced by permission.
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bone-targeting TNAP suggest that this is a
potentially life-saving treatment for severe
HPP, with potential to improve skeletal
and dental function in less-impaired
individuals with HPP (Millán et al., 2008;
Whyte et al., 2012).
Bone Resorption
Gorham-Stout Disease

Gorham-Stout disease (GSD), also
known as massive osteolysis, vanishing
or disappearing bone disease, is an
extremely rare disorder (MIM 123880).
The first patient was described in 1938,
and in 1955, Gorham and Stout described
the disease as “angiomatosis,” or
proliferation of small, thin-walled blood
vessels (Gorham and Stout, 1955). With
about 200 cases reported in the literature,
much about GSD remains unknown.
Histopathologically, the disease is a
benign vascular proliferation of endothelial
channels within bone, leading to extreme
thinning of bony trabeculae, osteoclastmediated resorption, and replacement
of bone with fibrous tissue. Gorham and
Stout postulated that hemangiomatosis
led to hyperemia, causing excessive bone
destruction. Hypotheses have included
local hypoxia/acidosis and endothelial
dysplasia (Heyden et al., 1977; Young
et al., 1983), enhanced osteoclastic activity or
increased sensitivity of osteoclast precursors
to humoral factors (e.g., IL-1, IL-6, and
TNF-α) (Devlin et al., 1996; Moller
et al., 1999; Hirayama et al., 2001), or
trauma (Al-Jamali et al., 2012). Another
hypothesis proposes GSD as a form of
lymphangiomatosis, a disease of soft tissue
secondary to aberrant proliferation of
lymphatic vasculature, placing these diseases
on the same pathophysiologic spectrum.
GSD occurs sporadically, without
apparent predilection for age, race, or
gender. Most cases occur in individuals
under the age of 40 yr, affecting
mostly children and young adults. The
disease can be progressive (Fig. 6) and
lethal when associated with extensive
involvement of the ribs, vertebrae, and
pleural effusions. However, in some
cases, it may be self-limiting. GSD can be
monostotic or polyostotic; affected areas
include the shoulder, pelvis, scapula,
16S

clavicle, ribs/sternum, femur, and skull.
About 30% of reported patients with GSD
have maxillofacial involvement, most
frequently in the mandible (Kiran and
Anupama, 2011). Pain is not a common
finding; however, during the acute
resorptive phase, pain, swelling, and
progressive deformity may be present.
In the dentoalveolar region, findings
may include mobile teeth, malocclusion,
mandibular deviation, bony deformity,
and pathologic fractures (Fig. 6).
Radiographically, bone undergoes
a series of changes in GSD. The first
stage is marked by patchy bone with
intramedullary and subcortical lucencies.
In the second stage, new areas of lucency
appear, with confluence of the lesions.
The third stage involves adjacent soft
tissues and cortical breakdown. The
last stage results in complete resorption
of bone and replacement with fibrous
tissue. Magnetic resonance imaging
(MRI) shows low signal intensity on
T1-weighted imaging and high signal
intensity on T2, with enhancement
on contrast imaging (Ruggieri et al.,
2011). Technetium bone scan is not a
reliable modality, since intensity is stagedependent. In the maxillofacial region,
panoramic radiographs and CT scans
are preferred for monitoring disease
progression. While tooth resorption has
not been reported, tooth loss may result
from reduced alveolar bone.
Knowledge gaps in pathophysiology
have prevented standardized
treatment guidelines for GSD and
lymphangiomatosis. Surgery is
necessary for pathologic fractures and
reconstruction after massive resorption.
Prostheses may offer advantages over
bone grafts because of the potential
for recurrent osteolysis. Radiotherapy
may limit disease spread by inhibiting
the proliferation of disease-causing
cells (Lowing et al., 2007). Medical
therapies include bisphosphonates and
interferon gamma; however, neither
has demonstrated definitive benefit
(Kuriyama et al., 2010). Additional studies
have focused on the proliferation of
endothelial cells, and the role of the
mTOR pathway in lymphangiogenesis,
leading to new potential therapeutic

targets (Reinglas et al., 2011). Prognosis
depends on the extent and location of
affected areas. Mild disease may stabilize
and ultimately reverse over time, while
severe cases involving the craniofacial
and/or thoracic areas may be fatal.
Conclusion
In this review, we outlined the effects
of rare skeletal diseases on the DOC
complex, focusing on 4 physiologic
processes exemplified by specific genetic
defects: FD as a defect in progenitor cell
differentiation, OI caused by defective
matrix production, FTC/HHS and
HPP as mineralization disorders, and
GSD as an example of excessive bone
resorption (Fig. 1). From these examples,
it is apparent that the formation and
function of the skeleton and dentition are
compromised when defects arise in any
one of these processes. Other rare bone
diseases with DOC effects are summarized
in Appendix Table 1.
In addition to the conditions covered
here, numerous undiagnosed skeletal
diseases exist. Overlap between the
underlying pathophysiology of these
etiologically elusive conditions with
that of known diseases may point to
commonalities in their mechanisms.
By understanding how defects in the
development and maintenance of bones
and teeth are subverted to cause disease,
we aim to broaden the understanding,
diagnosis, and treatment of rare skeletal
diseases sharing underlying mechanisms.
This is a paradigm currently used by
the NIH Undiagnosed Disease Program
(Office of Rare Disease Research; http://
rarediseases.info.nih.gov/) and a goal
of skeletal and craniofacial researchers
elsewhere. This approach has led to the
diagnosis of newly recognized diseases
such as arterial calcification due to
deficiency of CD73 (ACDC; MIM 211800),
and identification of causative mutations
in rare diseases including Raine syndrome
(MIM 259775) and Winchester syndrome
(MIM 277950).
When new rare skeletal diseases are
recognized, it is important for these
patients to be referred to a craniofacial/
dental team for clinical evaluation,
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Figure 6.
Gorham-Stout disease (GSD). Progressive destruction of the mandible in an individual with GSD, initially presenting at age 4 yr with mobility
of left mandibular primary teeth, and premature exfoliation of the left mandibular primary first molar. (A) Panoramic radiograph, age 6 yr.
Note normal complement of permanent teeth (left mandibular primary first molar #L missing) and abnormal left mandibular condyle. (B)
Computed tomography (CT), age 6 yr. Destruction of normal cortical architecture of mandibular condyle, ramus, and body, bilaterally (white
arrows). (C) Panoramic radiograph, age 7 yr (post-treatment with Interferon-α2b and zoledronic acid). Further bony changes with complete
loss of left mandibular angle (white arrow). (D) CT, age 7 yr. Remodeling changes of the left mandibular condyle and ramus (white arrows).
(E) Panoramic radiograph, age 10 yr. Loss of bony continuity in the left mandible (white arrow); teeth appear to be “floating.” Permanent
tooth formation has progressed (left mandibular canine, white star). (F) CT, age 10 yr. Tooth buds appear to hold remaining bone together in
left mandible. (G) CT, age 12 yr. Interval disease progression and bone loss of the bilateral mandible. Radiographs courtesy of Dr. Leonard B.
Kaban, Massachusetts General Hospital, Department of Oral and Maxillofacial Surgery, Boston, MA, USA.
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the collection of clinical materials for
translational studies, the monitoring of
development over time, and treatment
when possible. Only through this
careful approach can we accomplish 3
issues of paramount importance: (1) to
provide answers and appropriate care to
individuals suffering from conditions that
have eluded diagnosis, (2) to advance
medical knowledge about rare diseases
of the skeleton and dentition, and (3) to
develop and improve treatments for these
diseases.
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